Wall Street analyst estimates for Quoin Pharmaceuticals, Ltd. (QNRX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-1.63 | ||
| 2026-08-14 | $-1.90 | $-1.83 | -3.8% |
| 2026-05-07 | $-1.77 | $-1.80 | +1.7% |
| 2026-03-26 | $-14.80 | $-6.42 | -130.5% |
| 2025-11-06 | $-6.71 | $-6.36 | -5.5% |
| 2025-08-07 | $-6.28 | $-6.83 | +8.1% |
| 2025-05-13 | $-6.50 | $-3.85 | -68.8% |
| 2025-03-13 | $-12.24 | $-0.50 | -2348.0% |
Valuation Ratios
| Price / Book | 3.58 |
| EV / EBITDA | -0.57 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -$280000 | 0 | -$280000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $89130 | $104223 | $125720 | $227055 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$369130 | -$104223 | -$405720 | -$227055 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $8.3M | $5.9M | $8.3M | $45650 | $244155 | $1.6M | $2.7M | $3.3M | $3.6M | $9.8M |
| Selling, General & Admin | $8.0M | $4.2M | $8.0M | $1.5M | $1.4M | $4.5M | $6.6M | $6.1M | $5.9M | $6.5M |
| Operating Expenses | $16.2M | $10.1M | $16.2M | $1.6M | $1.7M | $6.1M | $9.3M | $9.4M | $9.5M | $16.3M |
| Operating Income | $15.3M | $10.2M | $15.3M | -$1.6M | -$1.7M | -$6.1M | -$9.3M | -$9.4M | -$9.5M | -$16.3M |
| EBITDA | -$3.9M | -$7.8M | -$5.5M | -$1.5M | -$1.6M | -$20.3M | -$8.6M | -$8.6M | -$8.9M | -$15.7M |
| Interest Expense | 0 | 0 | 0 | $412292 | $1.2M | $1.1M | $714081 | 0 | 0 | 0 |
| Pre-tax Income | $15.3M | $10.2M | $15.3M | -$1.6M | -$2.1M | -$21.5M | -$9.4M | -$8.7M | -$9.0M | -$15.8M |
| Income Tax | $147942 | -$1.2M | -$161141 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | $15.3M | $10.2M | $15.3M | -$1.6M | -$2.1M | -$21.5M | -$9.4M | -$8.7M | -$9.0M | -$15.8M |
| EPS | $-160847.00 | $-257489.00 | $-158862.00 | $-16307.00 | $-1290.96 | $-2490.26 | $-11.42 | $-11781.00 | $-2352.81 | $-10.63 |
| EPS (Diluted) | $-160847.00 | $-257489.00 | $-158862.00 | $-16307.00 | $-1290.96 | $-2490.26 | $-11.42 | $-11781.00 | $-2352.81 | $-10.63 |
| Shares Outstanding (Diluted) | $24 | $30 | $35 | $289 | $1634 | $8624 | $823706 | $735 | $3827 | $1.5M |
Price
| Price | $7.01 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CYCN · KTTA · NBY · PLRZ · PMCB · RADX · TCRT
Explore sector: Healthcare · Biotechnology
More sections of QNRX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks